The UK’s post-Brexit economy risks missing out on merger and acquisition deals, with investors shying away from political risk in the wake of the June 23rd vote.
Early-stage M&A activity jumped 19.8% in mainland Europe in the four weeks after Brexit.
But deal activity in Britain fell 7.4% during the same period, according to a report by M&A analysts Intralinks.
And that trend looks set to continue. Fewer investors want to take a risk on UK assets before the country’s new relationships with its trading partners are thrashed out.
Here is Intralinks on its survey of more than 1,000 dealmakers:
“While a majority of respondents expect demand for European assets over the next six months either to remain the same or increase as a result of Brexit, their responses are very different when asked about demand for UK assets.
A clear majority expects demand for UK assets to decrease over the next six months as a result of Brexit, with German respondents being the most negative. Clearly most dealmakers feel that uncertainty over the impact of Brexit on the UK outweighs the benefits of reduced valuations and a weaker UK currency.”
Full Content: Yahoo Finance
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas